全文获取类型
收费全文 | 20418篇 |
免费 | 1166篇 |
国内免费 | 148篇 |
专业分类
耳鼻咽喉 | 187篇 |
儿科学 | 472篇 |
妇产科学 | 705篇 |
基础医学 | 2302篇 |
口腔科学 | 546篇 |
临床医学 | 1641篇 |
内科学 | 5043篇 |
皮肤病学 | 406篇 |
神经病学 | 2141篇 |
特种医学 | 897篇 |
外科学 | 3167篇 |
综合类 | 59篇 |
一般理论 | 1篇 |
预防医学 | 726篇 |
眼科学 | 371篇 |
药学 | 1242篇 |
中国医学 | 28篇 |
肿瘤学 | 1798篇 |
出版年
2023年 | 183篇 |
2022年 | 157篇 |
2021年 | 553篇 |
2020年 | 437篇 |
2019年 | 521篇 |
2018年 | 664篇 |
2017年 | 472篇 |
2016年 | 527篇 |
2015年 | 605篇 |
2014年 | 847篇 |
2013年 | 1034篇 |
2012年 | 1552篇 |
2011年 | 1579篇 |
2010年 | 883篇 |
2009年 | 787篇 |
2008年 | 1246篇 |
2007年 | 1284篇 |
2006年 | 1222篇 |
2005年 | 1148篇 |
2004年 | 1091篇 |
2003年 | 929篇 |
2002年 | 830篇 |
2001年 | 292篇 |
2000年 | 327篇 |
1999年 | 281篇 |
1998年 | 169篇 |
1997年 | 123篇 |
1996年 | 114篇 |
1995年 | 125篇 |
1994年 | 99篇 |
1993年 | 83篇 |
1992年 | 187篇 |
1991年 | 191篇 |
1990年 | 144篇 |
1989年 | 125篇 |
1988年 | 116篇 |
1987年 | 117篇 |
1986年 | 100篇 |
1985年 | 85篇 |
1984年 | 68篇 |
1983年 | 63篇 |
1982年 | 44篇 |
1981年 | 29篇 |
1980年 | 24篇 |
1979年 | 26篇 |
1978年 | 20篇 |
1974年 | 24篇 |
1973年 | 25篇 |
1972年 | 19篇 |
1970年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
Marco N. Iannone Stefano Stucchi Elia A. Turolla Chiara Beretta Samuele Ciceri Clizia Chinello Lisa Pagani Sergio Todde Patrizia Ferraboschi 《Journal of labelled compounds & radiopharmaceuticals》2022,65(3):48-62
In the last decade, the development of new radiopharmaceuticals for the imaging and therapy of prostate cancer has been a highly active and important area of research, especially focusing on the prostate-specific membrane antigen (PSMA), an antigen which is upregulated in prostate, as well as in other tumor cells. A large variety of PSMA ligands have been radiolabeled, to date. Among the various derivatives, PSMA-617 resulted to be one of the most interesting in terms of interaction with the antigen and clinical properties, and its lutetium-177 labeled version has recently been approved by regulatory agencies for therapeutic purposes. For this reasons, the radiolabeling with fluorine-18 of a PSMA-617 derivative might be of interest. Beside other methodologies to radiolabel macromolecules with fluorine-18, the “click-chemistry” approach resulted to be very useful, and the copper-catalyzed azide-alkyne cycloaddition (CuAAC) is considered one of most efficient and reliable. This paper proposes the synthesis of a suitable precursor for the radiolabeling with fluorine-18 of a new PSMA-617 derivative. The whole radiosynthetic procedure has been fully automated, and the final product, which proved to be stable in plasma, has been obtained with radiochemical yield and purity suitable for subsequent preclinical studies. 相似文献
3.
Derek K. Chu Romina Brignardello-Petersen Gordon H. Guyatt Cristian Ricci Jon Genuneit 《Pediatric allergy and immunology》2022,33(1):e13609
Network meta-analyses (NMAs) simultaneously estimate the effects of multiple possible treatment options for a given clinical presentation. For allergists to benefit optimally from NMAs, they must understand the process and be able to interpret the results. Through a worked example published in Pediatric Allergy and Immunology, we summarize how to identify credible NMAs and interpret them with a focus on recent innovations in the GRADE approach (Grading of Recommendations Assessment, Development, and Evaluation). NMAs build on traditional systematic reviews and meta-analyses that consider only direct paired comparisons by including indirect evidence, thus allowing the simultaneous assessment of the relative effect of all pairs of competing alternatives. Our framework informs clinicians of how to identify credible NMAs and address the certainty of the evidence. Trustworthy NMAs fill a critical gap in providing key inferences using direct and indirect evidence to inform clinical decision making when faced with more than two competing courses of treatment options. This document will help allergists to identify trustworthy NMAs to enhance patient care. 相似文献
4.
Foc Emanuele Fornari Chiara Arsuffi Stefania Vetrano Maria Chiara Calza Stefano Renzetti Stefano Copeta Silvia Berruti Alfredo Castelli Francesco Compostella Silvia Quiros-Roldan Eugenia 《AIDS and behavior》2022,26(9):2920-2930
AIDS and Behavior - People living with chronic disease (PLWCD) are the frailest category, both for the risk of severe COVID-19 illness and for the impact on the care continuum. Aim of this study... 相似文献
5.
6.
Annelies Verbiest Inne Renders Stefano Caruso Gabrielle Couchy Sylvie Job Annouschka Laenen Virginie Verkarre Nathalie Rioux-Leclercq Patrick Schöffski Yann Vano Reza-Thierry Elaidi Evelyne Lerut Maarten Albersen Stéphane Oudard Wolf-Hervé Fridman Catherine Sautès-Fridman Laurence Albigès Agnieszka Wozniak Benoit Beuselinck 《Clinical genitourinary cancer》2019,17(5):e981-e994
IntroductionRecent trials have suggested predictive biomarkers in advanced clear-cell renal cell carcinoma (accRCC): International Metastatic RCC Database Consortium (IMDC) good risk or angiogenic gene signature for sunitinib and IMDC intermediate/poor risk for ipilimumab-nivolumab and T-effector cell signature or sarcomatoid dedifferentiation for atezolizumab-bevacizumab. We hypothesized that earlier described molecular subtypes, ccrcc1 to ccrcc4, could provide similar information as a single generic biomarker and molecularly characterize the heterogeneous intermediate-risk group.Patients and MethodsPatients with accRCC treated with systemic therapies were included. We assessed associations between the 5 biomarkers and their impact on progression-free survival (PFS) and response rate (RR) on first-line sunitinib or pazopanib. The cutoff percentage of sarcomatoid dedifferentiation with optimal discriminative value was determined.ResultsIn total, 430 patients were included (163 with molecular data). The molecular ccrcc2 subtype identified tumors with higher angiogenic gene expression across IMDC risk groups: prevalence was high in IMDC good risk and low in IMDC poor risk (P < .001). Molecular subtype, IMDC, and angiogenic gene expression had comparable C-indices to predict PFS and RR (range, 60%-66%). The ccrcc2 subtype and angiogenic gene expression were positive predictors of PFS in IMDC intermediate-risk patients (P = .006; P = .04). Immune signature did not differ between IMDC groups, but was strongly correlated with molecular subtype (P = .8 and P = .0007). A cutoff value of 25% sarcomatoid differentiation discriminated tumors with distinct molecular characteristics and therapeutic sensitivity.ConclusionIn accRCC, molecular subtypes can explain differences in IMDC risk group, expression of angiogenesis and immune response genes, and sarcomatoid dedifferentiation. They can identify molecularly different patient populations within the heterogeneous IMDC intermediate group and select patients for systemic therapies. 相似文献
7.
8.
9.
Zumel-Marne Angela Kundi Michael Castaño-Vinyals Gemma Alguacil Juan Petridou Eleni Th Georgakis Marios K. Morales-Suárez-Varela Maria Sadetzki Siegal Piro Sara Nagrani Rajini Filippini Graziella Hutter Hans-Peter Dikshit Rajesh Woehrer Adelheid Maule Milena Weinmann Tobias Krewski Daniel ′t Mannetje Andrea Momoli Franco Lacour Brigitte Mattioli Stefano Spinelli John J. Ritvo Paul Remen Thomas Kojimahara Noriko Eng Amanda Thurston Angela Lim Hyungryul Ha Mina Yamaguchi Naohito Mohipp Charmaine Bouka Evdoxia Eastman Chelsea Vermeulen Roel Kromhout Hans Cardis Elisabeth 《Journal of neuro-oncology》2020,147(2):427-440
Journal of Neuro-Oncology - We used data from MOBI-Kids, a 14-country international collaborative case–control study of brain tumors (BTs), to study clinical characteristics of the tumors in... 相似文献